SBIR PHASE II: SITE-SPECIFIC ANTIBODIES FOR GLCNACYLATED PROTEINS IN CANCER
SBIR PHASE II: SITE-SPECIFIC ANTIBODIES FOR GLCNACYLATED PROTEINS IN CANCER
批准号:
8765280
负责人:
HYESOOK KIM
金额:
$99.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-13 至 2015-09-12
关键词:
AntibodiesAntibody FormationAntigensAntineoplastic AgentsApoptosisBreast Cancer CellCell Cycle RegulationCellsDNA DamageDetectionDevelopmentDiseaseEstrogen Receptor alphaExcisionHumanMalignant NeoplasmsModificationMusNormal CellO-GlcNAc transferasePeptide antibodiesPeptidesPhasePhosphorylationPhysiologyPlayProductionProtein p53ProteinsProto-Oncogene Proteins c-mycRoleSerineSignal TransductionSignal Transduction PathwaySiteSmall Business Innovation Research GrantThreonineUbiquitinc-myc Genescancer cellcell growthinhibitor/antagonistmonoclonal antibody productionpeptide O-linked N-acetylglucosamine-beta-N-acetylglucosaminidasepolyclonal antibodypreventprotein functionresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
O-GlcNAcylation of proteins plays a critical role in cell cycle regulation, apoptosis and signal transduction. Modification of O-GlcNAcylation of proteins by O-GlcNAc transferase is reversible by the activity of O-GlcNAcase. Addition and removal of O-GlcNAc moiety to serine or threonine regulate the function of proteins directly or via decreased phosphorylation. O-GlcNAcylation of c-myc proteins induces ubiquitin-dependent c-myc degradation. GlcNAcylation of p53 prevents p53 degradation and stabilizes p53 proteins, which are beneficial in cancer cells by arresting cell growth and inducing apoptosis in response to DNA damage. To elucidate functions of O-GlcNAcylation of the proteins it is necessary to develop site-specific antibodies for O-GlcNAcylated proteins. Few site-specific antibodies have been successfully produced so far. A lack of site-specific O-GlcNAcylated Abs prevents facile detection and quantitation of the site to elucidate the function of O-GlcNAcylated molecules in physiology and disease. Availability of O-GlcNAcylation site-specific antibodies will facilitate mechanistic studies on O-GlcNAcylation ¿ and phosphorylation-dependent signal transduction pathway in cancer, which will result in development of O-GlcNAcylation-inducing anti-cancer drugs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IGF::OT::IGF R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)
-
批准号:9152579
-
项目类别:
-
资助金额:$29.91万
-
财政年份:2015
-
负责人:HYESOOK KIM
-
依托单位:
SBIR PHASE II: SITE-SPECIFIC ANTIBODIES FOR GLCNACYLATED PROTEINS IN CANCER
-
批准号:9915346
-
项目类别:
-
资助金额:$1.03万
-
财政年份:2013
-
负责人:HYESOOK KIM
-
依托单位:
SBIR TOPIC 294 PHASE I - DEVELOPMENT OF GLYCOSYLATION-SPECIFIC RESEARCH REAGENTS
-
批准号:8353821
-
项目类别:
-
资助金额:$14.75万
-
财政年份:2011
-
负责人:HYESOOK KIM
-
依托单位:
海外基金